The estimated Net Worth of Daniel R Marshak is at least $85.9 Thousand dollars as of 6 August 2014. Daniel Marshak owns over 41,965 units of InVivo Therapeutics Corp stock worth over $27,971 and over the last 21 years he sold NVIV stock worth over $57,915. In addition, he makes $0 as Independent Director at InVivo Therapeutics Corp.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Daniel Marshak NVIV stock SEC Form 4 insiders trading
Daniel has made over 9 trades of the InVivo Therapeutics Corp stock since 2010, according to the Form 4 filled with the SEC. Most recently he exercised 41,965 units of NVIV stock worth $796,496 on 6 August 2014.
The largest trade he's ever made was exercising 41,965 units of InVivo Therapeutics Corp stock on 6 August 2014 worth over $796,496. On average, Daniel trades about 3,058 units every 44 days since 2003. As of 6 August 2014 he still owns at least 87,410 units of InVivo Therapeutics Corp stock.
You can see the complete history of Daniel Marshak stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Daniel Marshak biography
Dr. Daniel R. Marshak Ph.D. serves as Independent Director of the Company. He has served as part-time Chief Technology Officer to Phase Scientific International Ltd., a medical device and clinical diagnostics company, since 2018. He most recently served in a full-time role as Senior Vice President and Chief Scientific Officer for PerkinElmer, Inc., a human and environmental health company, until September 2014. Prior to joining PerkinElmer in 2006, Dr. Marshak was Vice President and Chief Technology Officer, Biotechnology, for Cambrex Corporation and earlier, Chief Scientific Officer at Osiris Therapeutics Inc. Dr. Marshak has received numerous awards for scientific and academic achievements and is named as inventor on six issued U.S. patents. Dr. Marshak has served on the Board of Directors of Tecan Group, a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics and clinical diagnostics, since 2018. He also serves on the Board of Directors of a private, early-stage company, LifeVault Bio. Dr. Marshak is the author of more than 100 scientific publications, including one textbook, and has been the editor of five monographs. He held an appointment as Adjunct Associate Professor at the Johns Hopkins University School of Medicine, served as Senior Staff Investigator at Cold Spring Harbor Laboratory, and previously taught graduate biochemistry as an Assistant Professor at the State University of New York, now Stony Brook University. Dr. Marshak received his B.A. degree in biochemistry and molecular biology from Harvard University, and he holds a Ph.D. in biochemistry and cell biology from The Rockefeller University. Dr. Marshak brings to our Board significant industry experience and a deep understanding of the science and technology behind our business.
How old is Daniel Marshak?
Daniel Marshak is 63, he's been the Independent Director of InVivo Therapeutics Corp since 2014. There are 5 older and 4 younger executives at InVivo Therapeutics Corp. The oldest executive at InVivo Therapeutics Holdings Corp is Richard Roberts, 76, who is the Independent Director.
What's Daniel Marshak's mailing address?
Daniel's mailing address filed with the SEC is 940, Winter Street, Lincoln, Middlesex County, Massachusetts, 02451, United States.
Insiders trading at InVivo Therapeutics Corp
Over the last 14 years, insiders at InVivo Therapeutics Corp have traded over $11,891,061 worth of InVivo Therapeutics Corp stock and bought 364,908 units worth $191,940 . The most active insiders traders include Francis Reynolds, Robert Langer, and Sean F. Moran. On average, InVivo Therapeutics Corp executives and independent directors trade stock every 24 days with the average trade being worth of $10,438. The most recent stock trade was executed by Brice Foose on 5 February 2023, trading 330,000 units of NVIV stock currently worth $122,100.
What does InVivo Therapeutics Corp do?
about invivo therapeutics invivo therapeutics holdings corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. the company was founded in 2005 with proprietary technology co-invented by robert langer, sc.d., professor at massachusetts institute of technology, and joseph p. vacanti, m.d., who then was at boston children’s hospital and who now is affiliated with massachusetts general hospital. in 2011, the company earned the david s. apple award from the american spinal injury association for its outstanding contribution to spinal cord injury medicine. in 2015, the company’s investigational neuro-spinal scaffold received the 2015 becker’s healthcare spine device award. the publicly-traded company is headquartered in cambridge, ma. for more details, visit www.invivotherapeutics.com. about the neuro-spinal scaffold™ following acute spinal cord injury, surgical implantation of the biodegradable neuro-spinal scaffold wi
What does InVivo Therapeutics Corp's logo look like?
Complete history of Daniel Marshak stock trades at InVivo Therapeutics Corp and Revvity
InVivo Therapeutics Corp executives and stock owners
InVivo Therapeutics Corp executives and other stock owners filed with the SEC include:
-
Richard Toselli,
President, Chief Executive Officer, Director, Chief Medical Officer -
Dr. Richard M. Toselli,
Pres, CEO, Chief Medical Officer & Director -
Richard Christopher,
Chief Financial Officer -
Richard C. Christopher,
CFO & Treasurer -
C. Ann Merrifield,
Non-Executive Independent Chairman of the Board -
Robert Rosenthal,
Independent Director -
Richard Roberts,
Independent Director -
Christina Morrison,
Independent Director -
Daniel Marshak,
Independent Director -
Dr. Louis Vaickus FACP, M.D.,
Consultant -
Heather Hamel,
VP of Legal Affairs & Bus. Devel. and Corp. Sec. -
William D'Agostino PE,
Sr. VP of Operations -
Dr. Joseph Philip Vacanti,
Co-Founder -
Dr. Robert S. Langer Jr., Ph.D., Sc.D., SCD,
Co-Founder & Member of Scientific Advisory Board -
Tamara L Joseph,
SVP, General Counsel -
Christopher Mc Nulty,
Chief Financial Officer -
Thomas R Ulich,
Chief Scientific Officer -
Masuoka K. Lorianne,
Chief Medical Officer -
Jeffrey S. Hatfield,
Director -
Steven F Mcallister,
Chief Financial Officer -
Kenneth Di Pietro,
Director -
Pamela J Stahl,
Chief Commercial Officer -
Mark D Perrin,
CHIEF EXECUTIVE OFFICER -
John A Jr Mccarthy,
Director -
Bob Rosenthal,
Director -
Brice Foose,
10% owner -
Brian Hess,
Chief Technology Officer -
Sean F. Moran,
Acting Chief Financial Officer -
Gregory D Perry,
Interim CFO -
Francis Reynolds,
CEO, CFO -
Michael J Astrue,
INTERIM CEO -
Adam K Stern,
Director -
Robert Langer,
10% owner -
Edward Wirth,
Chief Science Officer -
George Nolen,
Director -
Heather Hamel,
Chief Legal Officer and GC